对早期结直肠癌的补充因子D和BCL2的组合抑制
Shahrose Rahman1, Arthur G Affleck1, Rebecca A Ruhl2
1Department of Surgery, Oregon Health and Science University, Portland, Oregon.
Diseases of the colon and rectum
|March 13, 2024
概括
这项研究发现,补充因子D和BCL2在早期发病的结直肠癌中升高. 在小鼠中抑制这些基因减缓了瘤生长,但引起了毒性,这表明了在仔细监测下潜在的治疗策略.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 遗传学 遗传学 是一个
背景情况:
- 瘤免疫微环境在早期发作的结直肠癌和晚期发作的结直肠癌之间存在差异,影响瘤的进展.
- 包括补充因子D在内的特定基因在早期发病的结直肠癌患者中表达的增加.
研究的目的:
- 为了验证早期与晚期结直肠癌的差异性免疫基因表达.
- 通过使用临床前模型,评估针对早期结直肠癌上调的基因的向药物疗效.
主要方法:
- 追溯性队列研究分析瘤RNA从甲固定型氨酸嵌入样本.
- 免疫组织化学用于基因表达和功能验证.
- 在小鼠模型中进行了体内临床前瘤研究,这些小鼠模型接受了补充因子D和BCL2抑制剂的治疗.
主要成果:
- 补充因子D和BCL2在早期发作的结直肠癌中被证实是升高的.
- 结合抑制补充因子D (danicopan) 和BCL2 (venetoclax) 减少了小鼠模型中的瘤负担.
- 药物组合在临床前模型中诱导了可观察到的毒性.
结论:
- 早期发病相关基因补充因子D和BCL2的联合抑制显示出减缓结直肠癌生长的潜力.
- 该研究强调了早期结直肠癌的潜在治疗方法,承认样本大小和模型系统的局限性.
- 需要进一步的研究来优化这种组合疗法并减轻毒性.
更多相关视频
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
The Intrinsic Apoptotic Pathway
6.5K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.5K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K


